Submitted:
29 March 2024
Posted:
01 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Microorganisms, Culture Conditions and Preparation of Spent LAB Cultures (Postmetabolites)
2.2. Cell Cultures
- 1)
- Untreated cells, maintained in DMEM, serving as a control,
- 2)
- An experimental group of cells cultured in the presence of L. fermentum 53 postmetabolites in MRS broth (spent LAB cultures in MRS broth/ CFSs), dissolved at different concentration in DMEM,
- 3)
- Cells cultured in the presence of pure MRS broth, dissolved at different concentration in DMEM, in order to differentiate the effects of the products released by the bacteria from those of the MRS broth components.
2.3. Morphological and Cell Viability Tests (Crystal Violet Staining)
2.4. Mitotic Index Determination
2.5. Assessment of Transepithelial Electrical Resistance (TEER)
2.6. FACS Analysis of Cell Cycle
2.7. Actin Filaments Visualization
2.8. Statistical Analysis
3. Results
3.1. Positive Effect of L. fermentum 53 Postmetabolites on the Growth Characteristics of HT-29 Cells
3.2. TEER
3.3. In Vitro Effects of L. fermentum Postmetabolites on Cellular Morphology and Organization of Actin Cytoskeleton of HT-29 Cells
3.4. Effects of L. fermentum Postmetabolites on Cell Cycle of HT-29 Cells
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Culligan, E.P.; Hill, C.; Sleator, R.D. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog 2009, 1, 19. [Google Scholar] [CrossRef]
- Lee, J.E.; Lee, J.; Kim, J.H.; Cho, N.; Lee, S.H.; Park, S.B.; Koh, B.; Kang, D.; Kim, S.; Yoo, H.M. Characterization of the Anti-Cancer Activity of the Probiotic Bacterium Lactobacillus fermentum Using 2D vs. 3D Culture in Colorectal Cancer Cells. Biomolecules 2019, 9. [Google Scholar] [CrossRef] [PubMed]
- Westfall, S.; Lomis, N.; Prakash, S. Ferulic Acid Produced by Lactobacillus fermentum Influences Developmental Growth Through a dTOR-Mediated Mechanism. Mol Biotechnol 2019, 61, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Resta, S.C. Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling. J Physiol 2009, 587, 4169–4174. [Google Scholar] [CrossRef] [PubMed]
- Lacerda, D.C.; Trindade da Costa, P.C.; Pontes, P.B.; Carneiro Dos Santos, L.A.; Cruz Neto, J.P.R.; Silva Luis, C.C.; de Sousa Brito, V.P.; de Brito Alves, J.L. Potential role of Limosilactobacillus fermentum as a probiotic with anti-diabetic properties: A review. World J Diabetes 2022, 13, 717–728. [Google Scholar] [CrossRef] [PubMed]
- Green, M.; Arora, K.; Prakash, S. Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. Int J Mol Sci 2020, 21. [Google Scholar] [CrossRef] [PubMed]
- Kaunang, T.M.D.; Setiawan, A.A.; Mayulu, N.; Leonita, I.; Wijaya, A.; Yusuf, V.M.; Mahira, M.; Yudisthira, D.; Gunawan, W.B.; Taslim, N.A.; et al. Are probiotics beneficial for obese patients with major depressive disorder? Opinion for future implications and strategies. Front Nutr 2023, 10, 1205434. [Google Scholar] [CrossRef] [PubMed]
- Sheykhsaran, E.; Abbasi, A.; Ebrahimzadeh Leylabadlo, H.; Sadeghi, J.; Mehri, S.; Naeimi Mazraeh, F.; Feizi, H.; Bannazadeh Baghi, H. Gut microbiota and obesity: an overview of microbiota to microbial-based therapies. Postgrad Med J 2023, 99, 384–402. [Google Scholar] [CrossRef] [PubMed]
- Martin, F.P.; Wang, Y.; Sprenger, N.; Yap, I.K.; Lundstedt, T.; Lek, P.; Rezzi, S.; Ramadan, Z.; van Bladeren, P.; Fay, L.B.; et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008, 4, 157. [Google Scholar] [CrossRef]
- Kerry, R.G.; Patra, J.K.; Gouda, S.; Park, Y.; Shin, H.S.; Das, G. Benefaction of probiotics for human health: A review. J Food Drug Anal 2018, 26, 927–939. [Google Scholar] [CrossRef]
- Kataria, J.; Li, N.; Wynn, J.L.; Neu, J. Probiotic microbes: do they need to be alive to be beneficial? Nutr Rev 2009, 67, 546–550. [Google Scholar] [CrossRef] [PubMed]
- Snoeck, V.; Goddeeris, B.; Cox, E. The role of enterocytes in the intestinal barrier function and antigen uptake. Microbes Infect 2005, 7, 997–1004. [Google Scholar] [CrossRef] [PubMed]
- Klingberg, T.D.; Pedersen, M.H.; Cencic, A.; Budde, B.B. Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity. Appl Environ Microbiol 2005, 71, 7528–7530. [Google Scholar] [CrossRef]
- Eun, C.S.; Kim, Y.S.; Han, D.S.; Choi, J.H.; Lee, A.R.; Park, Y.K. Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. APMIS 2011, 119, 49–56. [Google Scholar] [CrossRef] [PubMed]
- Jariwala, R.; Mandal, H.; Bagchi, T. Indigenous lactobacilli strains of food and human sources reverse enteropathogenic E. coli O26:H11-induced damage in intestinal epithelial cell lines: effect on redistribution of tight junction proteins. Microbiology (Reading) 2017, 163, 1263–1272. [Google Scholar] [CrossRef] [PubMed]
- Ng, S.C.; Hart, A.L.; Kamm, M.A.; Stagg, A.J.; Knight, S.C. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15, 300–310. [Google Scholar] [CrossRef] [PubMed]
- Messaoudi, S.; Madi, A.; Prevost, H.; Feuilloley, M.; Manai, M.; Dousset, X.; Connil, N. In vitro evaluation of the probiotic potential of Lactobacillus salivarius SMXD51. Anaerobe 2012, 18, 584–589. [Google Scholar] [CrossRef] [PubMed]
- O'Hara, A.M.; Shanahan, F. Mechanisms of action of probiotics in intestinal diseases. ScientificWorldJournal 2007, 7, 31–46. [Google Scholar] [CrossRef] [PubMed]
- M Petrova, R.G. , L Dojchinovska, N Kirilov, I Iliev, S Antonova, N Hadjieva, I Ivanova, S Danova Lactic acid bacteria against pathogenic microbes. Trakia J Sci 2009, 7, 33–39. [Google Scholar]
- Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150, 76–85. [Google Scholar] [CrossRef] [PubMed]
- Stephanova, E.; Topouzova-Hristova, T.; Hazarosova, R.; Moskova, V. Halothane-induced alterations in cellular structure and proliferation of A549 cells. Tissue Cell 2008, 40, 397–404. [Google Scholar] [CrossRef] [PubMed]
- Scheppach, W.; Bartram, P.; Richter, A.; Richter, F.; Liepold, H.; Dusel, G.; Hofstetter, G.; Ruthlein, J.; Kasper, H. Effect of short-chain fatty acids on the human colonic mucosa in vitro. JPEN J Parenter Enteral Nutr 1992, 16, 43–48. [Google Scholar] [CrossRef] [PubMed]
- Kang, S.J.; Kim, M.J.; Son, D.Y.; Kang, S.S.; Hong, K.W. Effects of Spore-Displayed p75 Protein from Lacticaseibacillus rhamnosus GG on the Transcriptional Response of HT-29 Cells. Microorganisms 2022, 10. [Google Scholar] [CrossRef] [PubMed]
- Wu, H.; Xie, S.; Miao, J.; Li, Y.; Wang, Z.; Wang, M.; Yu, Q. Lactobacillus reuteri maintains intestinal epithelial regeneration and repairs damaged intestinal mucosa. Gut Microbes 2020, 11, 997–1014. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Alexander, P.B.; Wang, X.F. TGF-beta Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol 2017, 9. [Google Scholar] [CrossRef] [PubMed]
- Dehghani, N.; Tafvizi, F.; Jafari, P. Cell cycle arrest and anti-cancer potential of probiotic Lactobacillus rhamnosus against HT-29 cancer cells. Bioimpacts 2021, 11, 245–252. [Google Scholar] [CrossRef] [PubMed]
- Abedi, A.; Tafvizi, F.; Jafari, P.; Akbari, N. The inhibition effects of Lentilactobacillus buchneri-derived membrane vesicles on AGS and HT-29 cancer cells by inducing cell apoptosis. Sci Rep 2024, 14, 3100. [Google Scholar] [CrossRef] [PubMed]
- Vielfort, K.; Weyler, L.; Soderholm, N.; Engelbrecht, M.; Lofmark, S.; Aro, H. Lactobacillus decelerates cervical epithelial cell cycle progression. PLoS One 2013, 8, e63592. [Google Scholar] [CrossRef] [PubMed]
- Ramakrishna, B.S. Probiotic-induced changes in the intestinal epithelium: implications in gastrointestinal disease. Trop Gastroenterol 2009, 30, 76–85. [Google Scholar] [PubMed]
- Zyrek, A.A.; Cichon, C.; Helms, S.; Enders, C.; Sonnenborn, U.; Schmidt, M.A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007, 9, 804–816. [Google Scholar] [CrossRef] [PubMed]
- Cario, E.; Gerken, G.; Podolsky, D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132, 1359–1374. [Google Scholar] [CrossRef] [PubMed]
- Paveljsek, D.; Juvan, P.; Kosir, R.; Rozman, D.; Hacin, B.; Ivicak-Kocjan, K.; Rogelj, I. Lactobacillus fermentum L930BB and Bifidobacterium animalis subsp. animalis IM386 initiate signalling pathways involved in intestinal epithelial barrier protection. Benef Microbes 2018, 9, 515–525. [Google Scholar] [CrossRef] [PubMed]
- Bansal, T.; Alaniz, R.C.; Wood, T.K.; Jayaraman, A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci U S A 2010, 107, 228–233. [Google Scholar] [CrossRef] [PubMed]






Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).